FDA Continues To Quash Interest In Repros Therapeutics

Repros, previously Zonagen, and CEO Joe Padolski have a long and rocky track record. Credibility is an issue, and investors tend to give the company a wide berth when it comes to new unknowns. The Type C meeting, and consequently a timely NDA filing, are just that – new unknowns.

1 2
View single page >> |

Disclaimer:

Use of PropThink’s research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.